



Optimizing transition of care in SBS-IF:

Paediatric and adult expert perspectives
on GLP-2 analogue therapy

Friday, 12th September 2025 | 13:00–13:45 (CEST)

Elite Park Avenue Hotel,
Banquet Hall 1, Gothenburg, Sweden



Add to calendar

After the symposium, we are hoping
that attendees would have gained
better understanding of:

1

Early management and
PN independence across
SBS-IF care pathway

2

Treatment advances
and MDT care in SBS-IF

3

Paediatric to adult
SBS-IF care transition
with GLP-2 analogue

4

Optimization of current
and future SBS-IF care

PROGRAMME

**GLP-2 analogue therapy in SBS-IF:
Supporting continuity from
paediatric to adult care**



Dr Lorenzo Norsa (chair)

Vittore Buzzi Children's
Hospital, University of
Milan, Italy



Prof. Francisca Joly

Hospital Beaujon,
Université Paris Cité, France

Followed by interactive audience
Q&A and panel discussion

This educational symposium is initiated, organized, and funded by Takeda Pharmaceuticals Company Limited and is intended for healthcare professionals outside of the USA registered for CIIRTA only. This symposium is not affiliated with CIIRTA.

CEST: Central European Summer Time; CIIRTA: Congress of the International Intestinal Rehabilitation and Transplantation Association;
GLP-2: glucagon-like peptide 2; MDT: multidisciplinary team; PN: parenteral nutrition; SBS-IF: short bowel syndrome with intestinal failure.

© 2025 Takeda Pharmaceutical Company Limited. All rights reserved. Takeda and the Takeda Logo are registered trademarks of Takeda Pharmaceuticals Company Limited (<https://www.takeda.com>).

Date of preparation: August 2025 | VV-MEDMAT-123551

